血浆白介素-18水平升高与急性呼吸窘迫综合征他汀治疗临床试验中死亡率增加相关
该研究为对ARDS Network Statins for Acutely Injured Lungs from Sepsis随机对照试验的回顾性分析,纳入683例感染相关急性呼吸窘迫综合征患者,随机接受瑞舒伐他汀或安慰剂。基线血浆白介素-18≥800 pg/mL与60天死亡风险显著相关(HR 2.3,95%CI 1.7-3.1),第3天白介素-18较基线每升高一个log2单位,死亡风险增加(HR 2.3,95%CI 1.5-3.5)。随机分配到他汀组的患者更可能出现白介素-18升高。结论提示白介素-18升高与感染相关急性呼吸窘迫综合征死亡率增加相关。
要点
- 在感染相关急性呼吸窘迫综合征患者中,基线血浆白介素-18≥800 pg/mL与60天死亡率高度相关(HR 2.3,95%CI 1.7-3.1)。
- 第3天血浆白介素-18较基线每升高一个log2单位,死亡风险增加(HR 2.3,95%CI 1.5-3.5)。
- 随机分配至瑞舒伐他汀组的患者更可能出现血浆白介素-18水平升高。
- 合并急性肾损伤、休克、基线白介素-18水平低以及未接受全身皮质类固醇的患者更可能出现白介素-18升高。
- 在所有上述亚组中,随机分配至他汀治疗均与白介素-18升高相关。
适用人群与场景
- 感染相关急性呼吸窘迫综合征患者,来自ARDS Network Statins for Acutely Injured Lungs from Sepsis试验,共683例(占原试验人群92%),基线(第0天)有样本。
- 第3天有样本者588例。
诊断标准与关键阈值
- 基线血浆白介素-18水平≥800 pg/mL为关键阈值,与60天死亡率高度相关。
处置流程与药物剂量
- 随机分配瑞舒伐他汀或安慰剂,疗程至多28天或ICU出院后3天。
研究设计与关键结果
- 研究类型:对随机对照临床试验的回顾性分析;样本量683例(基线),588例(第3天);人群为感染相关急性呼吸窘迫综合征。
- 干预与对照:随机分配瑞舒伐他汀或安慰剂。
- 主要终点结果:基线血浆白介素-18≥800 pg/mL与60天死亡率相关,死亡风险比(HR)2.3(95%CI 1.7-3.1)。
- 关键次要终点:第3天血浆白介素-18较基线每升高一个log2单位,死亡风险增加(HR 2.3,95%CI 1.5-3.5)。
- 随机分配至他汀组的患者更可能出现血浆白介素-18升高;合并急性肾损伤、休克、低基线白介素-18及未接受全身皮质类固醇的患者更易出现白介素-18升高,且在各亚组中他汀随机分组均与白介素-18升高相关。
证据类型、等级与局限
- 证据类型:对随机对照临床试验的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 基线血浆白介素-18≥800 pg/mL可能有助于识别感染相关急性呼吸窘迫综合征中60天死亡风险更高的患者。
- 他汀随机分组与白介素-18升高相关,提示他汀可能影响炎症小体通路,但该分析为回顾性,不能据此改变他汀在ARDS中的临床使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: A high plasma level of inflammasome mediator interleukin-18 was associated with mortality in observational acute respiratory distress syndrome cohorts. Statin exposure increases both inflammasome activation and lung injury in mouse models. We tested whether randomization to statin therapy correlated with increased interleukin-18 in the ARDS Network Statins for Acutely Injured Lungs from Sepsis trial.
DESIGN: Retrospective analysis of randomized controlled clinical trial.
SETTING: Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis.
PATIENTS: Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population.
INTERVENTIONS: Random assignment of rosuvastatin or placebo for up to 28 days or 3 days after ICU discharge.
MEASUREMENTS AND MAIN RESULTS: We measured plasma interleukin-18 levels in all Statins for Acutely Injured Lungs from Sepsis patients with sample available at day 0 (baseline, n = 683) and day 3 (after randomization, n = 588). We tested the association among interleukin-18 level at baseline, rising interleukin-18, and the impact of statin therapy on 60-day mortality, adjusting for severity of illness. Baseline plasma interleukin-18 level greater than or equal to 800 pg/mL was highly associated with 60-day mortality, with a hazard of death of 2.3 (95% CI, 1.7-3.1). Rising plasma interleukin-18 was also associated with increased mortality. For each unit increase in log2 (interleukin-18) at day 3 compared with baseline, the hazard of death increased by 2.3 (95% CI, 1.5-3.5). Subjects randomized to statin were significantly more likely to experience a rise in plasma interleukin-18 levels. Subjects with acute kidney injury, shock, low baseline interleukin-18, and those not receiving systemic corticosteroids were more likely to experience rising interleukin-18. Randomization to statin therapy was associated with rising in interleukin-18 in all of those subsets, however.
CONCLUSIONS: Elevated baseline plasma interleukin-18 was associated with higher mortality in sepsis-induced acute respiratory distress syndrome. A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.
参考来源
- Rogers AJ, Guan J, Trtchounian A, et al. Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome. Crit Care Med. 2019. PMID: 31206358. doi:10.1097/CCM.0000000000003816
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。